Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate CareDx, Inc before investing.

In this article, we go over a few key elements for understanding CareDx, Inc’s stock price such as:

• CareDx, Inc’s current stock price and volume
• Why CareDx, Inc’s stock price changed recently
• Upgrades and downgrades for CDNA from analysts
• CDNA’s stock price momentum as measured by its relative strength

About CareDx, Inc (CDNA)

Before we jump into CareDx, Inc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI, a transplant quality tracking software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Want to learn more about CareDx, Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about CareDx, Inc.

What Caused CareDx, Inc Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 28, 2025, there was 1 analyst who downgraded CareDx, Inc’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate CareDx, Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on CareDx, Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

CareDx, Inc’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about CareDx, Inc (CDNA) by visiting AAII Stock Evaluator.

Relative Price Strength of CareDx, Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 28, 2025, CareDx, Inc has a weighted four-quarter relative price strength of -3.40%, which translates to a Momentum Score of 48 and is considered to be Average.

Want to learn more about how CareDx, Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

CareDx, Inc Stock Price: Bottom Line

As of December 1, 2025, CareDx, Inc’s stock price is $17.360, which is down 2.85% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like CareDx, Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.